Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 53Neoplasms 23Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Lung Neoplasms 12Head and Neck Neoplasms 11Neoplasm Metastasis 8Carcinoma, Squamous Cell 7Pancreatic Neoplasms 6Colorectal Neoplasms 6Stomach Neoplasms 5Esophageal Squamous Cell Carcinoma 5Prostatic Neoplasms 4Multiple Myeloma 4Esophageal Neoplasms 4Lymphoma 3Hematologic Neoplasms 3Glioblastoma 3Brain Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Melanoma 2Glioma 2Colonic Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × Afatinib × Clear all
NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 8 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Boehringer Ingelheim

Phase 3 Completed
364 enrolled 28 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Boehringer Ingelheim

Phase 3 Completed
345 enrolled 23 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡